FR13C0034I1 - - Google Patents

Info

Publication number
FR13C0034I1
FR13C0034I1 FR13C0034C FR13C0034I1 FR 13C0034 I1 FR13C0034 I1 FR 13C0034I1 FR 13C0034 C FR13C0034 C FR 13C0034C FR 13C0034 I1 FR13C0034 I1 FR 13C0034I1
Authority
FR
France
Prior art keywords
compounds
amyloid deposits
methods
relates
making
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
English (en)
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR13C0034I1 publication Critical patent/FR13C0034I1/fr
Application granted granted Critical
Publication of FR13C0034I2 publication Critical patent/FR13C0034I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR13C0034C 2006-03-30 2013-06-26 Derives de styrylpyridine et leurs applications a la liaison et a l'imagerie de plaques amyloides Active FR13C0034I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78715606P 2006-03-30 2006-03-30
PCT/US2007/007400 WO2007126733A2 (en) 2006-03-30 2007-03-26 Styrylpyridine derivatives and their use for binding and imaging amyloid plaques

Publications (2)

Publication Number Publication Date
FR13C0034I1 true FR13C0034I1 (pl) 2013-08-09
FR13C0034I2 FR13C0034I2 (fr) 2014-03-07

Family

ID=38326579

Family Applications (1)

Application Number Title Priority Date Filing Date
FR13C0034C Active FR13C0034I2 (fr) 2006-03-30 2013-06-26 Derives de styrylpyridine et leurs applications a la liaison et a l'imagerie de plaques amyloides

Country Status (34)

Country Link
US (3) US7687052B2 (pl)
EP (3) EP1999109B1 (pl)
JP (1) JP5290954B2 (pl)
KR (1) KR101376807B1 (pl)
CN (1) CN101522624B (pl)
AT (1) ATE539060T1 (pl)
AU (1) AU2007243712B2 (pl)
BR (1) BRPI0710225B1 (pl)
CA (1) CA2644530C (pl)
CR (1) CR10329A (pl)
CY (3) CY1113048T1 (pl)
DK (2) DK2363392T3 (pl)
EA (1) EA017898B1 (pl)
EC (1) ECSP088783A (pl)
ES (2) ES2378785T3 (pl)
FR (1) FR13C0034I2 (pl)
GT (1) GT200800201A (pl)
HR (2) HRP20120135T1 (pl)
HU (2) HUE032660T2 (pl)
IL (1) IL193567A (pl)
LT (1) LT2363392T (pl)
LU (1) LU92232I2 (pl)
MX (1) MX2008012527A (pl)
NO (2) NO342090B1 (pl)
NZ (1) NZ570887A (pl)
PL (2) PL1999109T3 (pl)
PT (2) PT1999109E (pl)
RS (2) RS52222B (pl)
SG (1) SG173338A1 (pl)
SI (2) SI2363392T1 (pl)
TW (1) TWI399366B (pl)
UA (1) UA97802C2 (pl)
WO (1) WO2007126733A2 (pl)
ZA (1) ZA200807955B (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ570887A (en) 2006-03-30 2011-05-27 Univ Pennsylvania Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
CA2699965A1 (en) * 2007-07-04 2009-01-08 Tohoku University Pet probe having an alkoxy group substituted by fluorine and hydroxy group
JP5603855B2 (ja) * 2008-04-04 2014-10-08 アビッド レディオファーマシューティカルズ、インク． 神経変成疾患の放射性薬剤による画像化
PL2381967T3 (pl) * 2008-12-31 2017-06-30 Avid Radiopharmaceuticals, Inc. Synteza styrylopirydyn radioznakowanych 18F z prekursorów tosylanowych i ich stabilne kompozycje farmaceutyczne
JP2012532164A (ja) * 2009-07-10 2012-12-13 バイエル ファーマ アクチエンゲゼルシャフト 放射性トレーサーの精製のための低‐中圧液体クロマトグラフィーの使用
EP2501696B1 (en) 2009-10-15 2016-12-28 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
AR079687A1 (es) * 2009-12-23 2012-02-15 Bayer Schering Pharma Ag Formulaciones adecuadas para el diagnostico por imagenes con pet
WO2011141515A1 (en) 2010-05-14 2011-11-17 Bayer Pharma Aktiengesellschaft Diagnostic agents for amyloid beta imaging
EP2575898B8 (en) * 2010-06-04 2021-04-21 Life Molecular Imaging SA Method for production of f-18 labeled amyloid beta ligand
EP2575900A1 (en) * 2010-06-04 2013-04-10 Piramal Imaging SA Method for production of f-18 labeled amyloid beta ligands
TWI504414B (zh) 2010-06-04 2015-10-21 Bayer Schering Pharma Ag 生產Ｆ－１８標記之Ａβ配位體之方法
EA022897B1 (ru) 2010-06-04 2016-03-31 Пирамаль Имэджинг Са СПОСОБ ПОЛУЧЕНИЯ F-18 МЕЧЕНЫХ Аβ ЛИГАНДОВ
CN101891674B (zh) * 2010-06-24 2012-11-14 山东大学 4-苯乙烯基吡啶类化合物及其制备方法与应用
US9259495B2 (en) * 2010-10-12 2016-02-16 Mayo Foundation For Medical Education And Research Imaging of meningiomas using phenylbenzothiazole, stilbene, or biphenylalkyne derivatives
US20140079635A1 (en) * 2011-03-30 2014-03-20 Case Western Reserve University Molecular probes for detecting lipid composition
AU2012245861A1 (en) * 2011-04-21 2013-10-17 The Regents Of The University Of California Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles
IN2014MN00875A (pl) 2011-10-19 2015-04-17 Piramal Imaging Sa
EP2836241B1 (en) 2012-04-10 2019-02-20 Lantheus Medical Imaging, Inc. Radiopharmaceutical synthesis methods
JP6099045B2 (ja) * 2013-04-30 2017-03-22 国立大学法人京都大学 トリアゾロピリミジン誘導体化合物
JP6041751B2 (ja) * 2013-05-07 2016-12-14 日本メジフィジックス株式会社 スチリルピリジン誘導体化合物
JP2014218454A (ja) * 2013-05-07 2014-11-20 日本メジフィジックス株式会社 スチリルピリジン誘導体化合物
CN103645254B (zh) * 2013-11-28 2015-01-07 江苏省原子医学研究所 一种Aβ斑块显像剂前体AV45的含量分析方法
PL3143011T3 (pl) * 2014-05-13 2021-07-19 F. Hoffmann-La Roche Ag Deuterowane związki heterocykliczne i ich zastosowanie jako środki obrazujące
CA2994178C (en) 2015-08-18 2024-03-19 The Regents Of The University Of California Nitroxide containing amyloid binding agents for imaging and therapeutic uses
US10300155B2 (en) 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
CN109400615B (zh) * 2017-08-18 2021-07-16 上海交通大学医学院附属新华医院 一种靶向β-淀粉样蛋白的香豆素类化合物及其制备与应用
CN108299287A (zh) * 2018-01-02 2018-07-20 北京师范大学 与Aβ斑块具有高亲和力的N2S2类吡啶基苯乙烯化合物
CN114805190A (zh) * 2022-06-08 2022-07-29 吉林大学第一医院 一种甲基苯胺类Aβ蛋白显像剂的双柱合成方法
WO2024107620A1 (en) 2022-11-14 2024-05-23 Eli Lilly And Company Polymorphic forms of florbetapir precursor av-105

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000963A1 (en) 1990-07-12 1992-01-23 Yoshitomi Pharmaceutical Industries, Ltd. Styryl compounds and use thereof as medicine
JPH0545875A (ja) * 1991-08-08 1993-02-26 Konica Corp 感光性組成物
US6020436A (en) * 1993-03-09 2000-02-01 The Chromaline Corporation Photosensitive resin composition
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
WO2001070667A1 (fr) * 2000-03-22 2001-09-27 Bf Research Institute, Inc. Sonde de diagnostic par image, a base d'azobenzene substitue ou d'un analogue de celui-ci, pour les maladies imputables a l'accumulation d'amyloide et composition pour le diagnostic par image le contenant
US8007954B2 (en) 2000-11-09 2011-08-30 The Trustees Of The University Of Pennsylvania Use of sulfur-containing fuels for direct oxidation fuel cells
JP2002182254A (ja) 2000-12-18 2002-06-26 Fuji Photo Film Co Ltd 非線形光学材料とその製造方法
EP1432453B1 (en) * 2001-08-27 2013-08-14 The Trustees of The University of Pennsylvania Stilbene derivatives and their use for binding and imaging amyloid plaques
KR20050036914A (ko) 2002-06-06 2005-04-20 트러스티스 오브 더 유니버시티 오브 펜실바니아 세라믹 음극 및 이의 제조 방법
WO2004016271A1 (en) * 2002-08-14 2004-02-26 Axxima Pharmaceuticals Ag Pyrimidones as antiviral agents
JP4482352B2 (ja) 2004-03-11 2010-06-16 本田技研工業株式会社 固体高分子型燃料電池
SI2213652T1 (sl) * 2004-12-17 2015-03-31 The Trustees Of The University Of Pennsylvania Derivati stilbena in njihova uporaba za vezavo in prikaz amiloidnih plakov
WO2006078384A2 (en) * 2004-12-17 2006-07-27 The Trustees Of The University Of Pennsylvania Stilbene derivatives and their use
EP1893245A4 (en) 2005-06-24 2009-06-24 Univ Pennsylvania RADIOACTIVELY MARKED PEGYLATION OF LIGANDS FOR USE AS A CONTRAST
NZ570887A (en) 2006-03-30 2011-05-27 Univ Pennsylvania Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
US20080253967A1 (en) * 2007-04-13 2008-10-16 Kung Hank F Halo-Stilbene Derivatives And Their Use For Binding And Imaging Of Amyloid Plaques

Also Published As

Publication number Publication date
CY2013024I1 (el) 2015-11-04
TW200838852A (en) 2008-10-01
EA017898B1 (ru) 2013-04-30
CA2644530A1 (en) 2007-11-08
BRPI0710225B1 (pt) 2021-07-13
US8506929B2 (en) 2013-08-13
US20080038195A1 (en) 2008-02-14
LU92232I9 (pl) 2019-01-15
DK2363392T3 (en) 2017-07-03
CY1113048T1 (el) 2015-11-04
SI1999109T1 (sl) 2012-04-30
NZ570887A (en) 2011-05-27
CY1119048T1 (el) 2018-01-10
CY2013024I2 (el) 2015-11-04
ZA200807955B (en) 2012-11-28
ES2628882T3 (es) 2017-08-04
MX2008012527A (es) 2008-10-14
GT200800201A (es) 2009-08-20
EA200870389A1 (ru) 2009-04-28
IL193567A0 (en) 2009-05-04
PL1999109T3 (pl) 2012-05-31
PT2363392T (pt) 2017-06-15
KR101376807B1 (ko) 2014-03-20
CN101522624B (zh) 2013-11-06
WO2007126733A3 (en) 2008-03-06
US20130129624A1 (en) 2013-05-23
LU92232I2 (fr) 2013-08-26
SG173338A1 (en) 2011-08-29
UA97802C2 (uk) 2012-03-26
ATE539060T1 (de) 2012-01-15
EP2363392A1 (en) 2011-09-07
FR13C0034I2 (fr) 2014-03-07
ECSP088783A (es) 2008-10-31
US8840866B2 (en) 2014-09-23
RS56171B1 (sr) 2017-11-30
EP2363392B1 (en) 2017-05-03
RS52222B (en) 2012-10-31
LT2363392T (lt) 2017-07-25
JP2009532349A (ja) 2009-09-10
EP2363391A1 (en) 2011-09-07
US20090123369A1 (en) 2009-05-14
CN101522624A (zh) 2009-09-02
KR20080106564A (ko) 2008-12-08
NO2018030I1 (no) 2018-09-11
HUE032660T2 (en) 2017-10-30
BRPI0710225A2 (pt) 2011-08-02
ES2378785T3 (es) 2012-04-17
PT1999109E (pt) 2012-03-16
PL2363392T3 (pl) 2017-10-31
NO20084590L (no) 2008-12-29
WO2007126733A2 (en) 2007-11-08
SI2363392T1 (sl) 2017-09-29
HRP20170857T1 (hr) 2017-12-01
US7687052B2 (en) 2010-03-30
HUS1300028I1 (hu) 2017-08-28
EP1999109B1 (en) 2011-12-28
CR10329A (es) 2008-10-29
JP5290954B2 (ja) 2013-09-18
HRP20120135T1 (hr) 2012-03-31
EP1999109A2 (en) 2008-12-10
IL193567A (en) 2014-03-31
AU2007243712A1 (en) 2007-11-08
TWI399366B (zh) 2013-06-21
AU2007243712B2 (en) 2013-01-10
DK1999109T3 (da) 2012-04-02
CA2644530C (en) 2015-05-19
NO342090B1 (no) 2018-03-19

Similar Documents

Publication Publication Date Title
LU92232I9 (pl)
MX2007007380A (es) Derivados de estilbeno y su uso para estudios de union y por imagenes de placas amiloides.
WO2006078384A3 (en) Stilbene derivatives and their use
WO2008073350A3 (en) Acetylene derivatives and their use for binding and imaging amyloid plaques
GB2443287B (en) Methods, compositions and formulations for the treatment of thyroid eye disease
EP2023926A4 (en) PYRIDONECARBOXAMIDE DERIVATIVES USEFUL FOR TREATING HYPERPROLIFERATIVE AND ANGIOGENESIS RELATED DISORDERS
WO2007033080A3 (en) Alzheimer's disease imaging agents
PT2050447T (pt) Forma de dosagem oral contendo entacapona
HUE059861T2 (hu) N-Szubsztituált 2,5-dioxo-azolin vegyületek a rák kezelésében való felhasználásra
WO2008003943A3 (en) Inhibition of alpha-synuclein aggregation
ZA200803666B (en) Method for stabilising pharmaceutical administration forms that contain miro-organisms
EP2401263A4 (en) SUBSTITUTED AZOL DERIVATIVES, PHARMACEUTICAL COMPOSITION WITH THE DERIVATIVES AND METHOD FOR THE TREATMENT OF MORBUS PARKINSON THEREWITH
HK1121378A1 (en) Compositions and methods for the treatment of addiction and other neuropsychiatric disorders
IL196561A0 (en) Compositions and methods for treating diabetes and neuropsychological dysfunction
EP1846432A4 (en) METHOD FOR MANUFACTURING TARGETED THERAPEUTIC AGENTS
WO2006136454A3 (de) Verwendung von inhibitorn der n-methyltransferasen in der therapie des parkinson-symdroms
WO2008050133A3 (en) Inhibition of beta-amyloid aggregation
UA91996C2 (ru) Производные стильбена и их применение для связывания и визуализации амилоидных бляшек
EP1942909A4 (en) METHODS OF TREATING RESPIRATORY DISORDERS
WO2010135493A3 (en) Alzheimer's disease imaging agents
EP1937242A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISEASES AND ADDITIVES
UA99579C2 (ru) АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С Tau, ФОСФОРИЛИРОВАННЫМ ПО СЕРИНУ 422 (pS422), ДЛЯ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ ТАУПАТИИ
IL184372A (en) Method for providing interferon ß
GB0620693D0 (en) Composition and methods for the treatment of degenerative disease